HomeCompareVECT vs MO

VECT vs MO: Dividend Comparison 2026

VECT yields 11.86% · MO yields 6.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MO wins by $34.0K in total portfolio value· pulled ahead in Year 8
10 years
VECT
VECT
● Live price
11.86%
Share price
$16.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.7K
Annual income
$2,485.28
Full VECT calculator →
MO
Altria Group Inc.
● Live price
6.27%
Share price
$67.02
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$77.7K
Annual income
$28,968.54
Full MO calculator →

Portfolio growth — VECT vs MO

📍 MO pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVECTMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VECT + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VECT pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VECT
Annual income on $10K today (after 15% tax)
$1,007.71/yr
After 10yr DRIP, annual income (after tax)
$2,112.49/yr
MO
Annual income on $10K today (after 15% tax)
$532.68/yr
After 10yr DRIP, annual income (after tax)
$24,623.26/yr
At 15% tax rate, MO beats the other by $22,510.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VECT + MO for your $10,000?

VECT: 50%MO: 50%
100% MO50/50100% VECT
Portfolio after 10yr
$60.7K
Annual income
$15,726.91/yr
Blended yield
25.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

VECT
Analyst Ratings
3
Buy
Consensus: Buy
Price Target
$18.00
+6.7% upside vs current
Range: $18.00 — $18.00
Altman Z
13.9
Piotroski
4/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-8.6% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VECT buys
0
MO buys
0
No recent congressional trades found for VECT or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVECTMO
Forward yield11.86%6.27%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$43.7K$77.7K
Annual income after 10y$2,485.28$28,968.54
Total dividends collected$18.2K$72.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$18.00$61.25

Year-by-year: VECT vs MO ($10,000, DRIP)

YearVECT PortfolioVECT Income/yrMO PortfolioMO Income/yrGap
1$11,886$1,185.54$10,558$768.31+$1.3KVECT
2$14,034$1,316.89$11,352$1,015.87+$2.7KVECT
3$16,470$1,453.25$12,482$1,367.86+$4.0KVECT
4$19,217$1,593.89$14,103$1,883.39+$5.1KVECT
5$22,300$1,738.05$16,472$2,664.91+$5.8KVECT
6$25,746$1,884.96$20,024$3,897.79+$5.7KVECT
7$29,582$2,033.87$25,537$5,933.74+$4.0KVECT
8← crossover$33,837$2,184.03$34,478$9,476.77$641.00MO
9$38,540$2,334.73$49,776$16,022.63$11.2KMO
10$43,723$2,485.28$77,699$28,968.54$34.0KMO

VECT vs MO: Complete Analysis 2026

VECTStock

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

Full VECT Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this VECT vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VECT vs SCHDVECT vs JEPIVECT vs OVECT vs KOVECT vs MAINVECT vs PMVECT vs BTIVECT vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.